Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

56.24 UNCHANGED

Streaming Delayed Price Updated: 8:00 PM EST, Jan 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	56.24
Bid (Size)	55.32 (100)
Ask (Size)	59.55 (100)
Prev. Close	56.24
Today's Range	56.24 - 56.24
52wk Range	35.22 - 57.58
Shares Outstanding	36,002
Dividend Yield	0.80%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Did CRMD Stock Crash 28% Today? ↗

January 08, 2026

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

Via Stocktwits

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

Performance

YTD	+1.9%	+1.9%
1 Month	+0.6%	+0.6%
3 Month	+15.6%	+15.6%
6 Month	+32.1%	+32.1%
1 Year	+31.3%	+31.3%

More News

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

Via Benzinga

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

Via Investor's Business Daily

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Via Benzinga

Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗

August 22, 2025

Via Investor's Business Daily

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Via Benzinga

Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)

July 29, 2025

Via MarketMinute

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Via Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Via Benzinga

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

Via Benzinga

Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe ↗

May 23, 2025

Via Benzinga

Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work ↗

May 20, 2025

Via Investor's Business Daily

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗

May 19, 2025

Via Benzinga

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗

May 08, 2025

Via Benzinga

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗

April 28, 2025

Via Stocktwits

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗

April 18, 2025

Via Benzinga

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Via Benzinga

Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? ↗

April 03, 2025

Via Benzinga

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In ↗

March 06, 2025

Via Stocktwits

Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 ↗

March 04, 2025

Via Stocktwits

Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 ↗

February 28, 2025

Via Benzinga

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗

February 17, 2025

Via Benzinga

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗

January 28, 2025

Via Stocktwits

Frequently Asked Questions

Is State Street SPDR S&P Pharmaceuticals ETF publicly traded?

Yes, State Street SPDR S&P Pharmaceuticals ETF is publicly traded.

What exchange does State Street SPDR S&P Pharmaceuticals ETF trade on?

State Street SPDR S&P Pharmaceuticals ETF trades on the New York Stock Exchange

What is the ticker symbol for State Street SPDR S&P Pharmaceuticals ETF?

The ticker symbol for State Street SPDR S&P Pharmaceuticals ETF is XPH on the New York Stock Exchange

What is the current price of State Street SPDR S&P Pharmaceuticals ETF?

The current price of State Street SPDR S&P Pharmaceuticals ETF is 56.24

When was State Street SPDR S&P Pharmaceuticals ETF last traded?

The last trade of State Street SPDR S&P Pharmaceuticals ETF was at 01/08/26 08:00 PM ET

What is the market capitalization of State Street SPDR S&P Pharmaceuticals ETF?

The market capitalization of State Street SPDR S&P Pharmaceuticals ETF is 2.02M

How many shares of State Street SPDR S&P Pharmaceuticals ETF are outstanding?

State Street SPDR S&P Pharmaceuticals ETF has 2M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.